达雷妥尤单抗联合RVd方案治疗新诊断多发性骨髓瘤:GRIFFIN研究安全性导入队列最终分析
GRIFFIN是一项2期研究,评估达雷妥尤单抗联合来那度胺/硼替佐米/地塞米松(D-RVd)用于适合移植的新诊断多发性骨髓瘤,包含安全性导入期和随机期。本次报告安全性导入队列(N=16)最终分析,中位随访40.8个月,涵盖D-R维持治疗。结果显示,巩固治疗后所有患者均缓解,9例(56.3%)达sCR,8例(50.0%)MRD阴性(10⁻⁵);维持治疗后15例(93.8%)达sCR,13例(81.3%)MRD阴性。估计36个月PFS率和OS率分别为78.1%和93.8%。安全性特征与达雷妥尤单抗和RVd一致。
要点
- D-RVd诱导、移植、巩固后D-R维持,在中位40.8个月随访中产生持久且加深的缓解。
- 维持治疗后sCR率93.8%,MRD阴性率(10⁻⁵)81.3%。
- 估计36个月PFS率78.1%,OS率93.8%。
核心结论
- 在中位随访40.8个月时,D-RVd方案获得持久缓解,且经D-R维持治疗后缓解进一步加深。
研究设计与样本
- 2期GRIFFIN研究的安全性导入队列,纳入16例适合移植的新诊断多发性骨髓瘤患者。
- 治疗方案包括4周期D-RVd诱导、大剂量美法仑联合自体干细胞移植、2周期D-RVd巩固和24个月D-R维持。
主要发现
- 巩固治疗结束时所有患者均缓解,最佳缓解为sCR者9例(56.3%),MRD阴性(10⁻⁵阈值)者8例(50.0%)。
- 维持治疗后最佳缓解为sCR者15例(93.8%),MRD阴性(10⁻⁵)者13例(81.3%)。
- 估计36个月无进展生存率和总生存率分别为78.1%和93.8%。
- 1例未达sCR的患者死于疾病进展。
- 观察到的安全性特征与达雷妥尤单抗和RVd一致。
临床怎么用
- D-RVd方案联合D-R维持治疗在适合移植的新诊断多发性骨髓瘤中显示出深度且持久的缓解,支持其在该人群中的应用。
局限性
- 安全性导入队列样本量小(N=16),非随机比较,结论需在随机期中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The phase 2 GRIFFIN study of daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) for transplant-eligible, newly diagnosed multiple myeloma included a safety run-in phase followed by a randomized phase. The ongoing randomized phase has met its prespecified primary end point of an improved stringent complete response (sCR) rate after consolidation for D-RVd (reported elsewhere). Final analysis of the safety run-in cohort is reported herein and provides longer follow-up (median, 40.8 months) encompassing daratumumab plus lenalidomide (D-R) maintenance therapy. Patients in the safety run-in cohort (N = 16) received 4 induction cycles (D-RVd), high-dose melphalan supported by autologous stem cell transplant, 2 consolidation cycles (D-RVd), and 24 months of maintenance (D-R). By the end of consolidation, all patients had responded, with a best response of sCR in 9 (56.3%) patients; 8 (50.0%) patients were minimal residual disease (MRD) negative (10‒5 threshold). After maintenance, 15 (93.8%) patients had achieved a best response of sCR, and 13 (81.3%) patients were MRD (10‒5) negative. Estimated 36-month progression-free and overall survival rates were 78.1% and 93.8%, respectively. One death from progressive disease occurred in the patient who did not achieve sCR. Observed safety profiles were consistent with daratumumab and RVd. With >3 years of median follow-up, D-RVd achieved durable responses that deepened with D-R maintenance. This study was registered at www.clinicaltrials.gov as #NCT02874742.
引用
- Voorhees PM, Rodriguez C, Reeves B, et al. Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Blood Adv. 2021. PMID: 33606004. doi:10.1182/bloodadvances.2020003642
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。